Scienture Holdings, Inc. Market Cap ($15.07 Million)
Market Cap & Net Worth: Scienture Holdings, Inc. (SCNX)
Scienture Holdings, Inc. market cap. Scienture Holdings, Inc. (NASDAQ:SCNX) has a market capitalization of $15.07 Million ($15.07 Million) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #25833 globally and #5441 in its home market, demonstrating a 16.25% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Scienture Holdings, Inc.'s stock price $3.22 by its total outstanding shares 41064146 (41.06 Million). Also see cash efficiency ratio of Scienture Holdings, Inc. for how efficiently the company converts equity into cash flow.
Scienture Holdings, Inc. Market Cap History (2015–2026)
Scienture Holdings, Inc. market cap history from 2015 to 2026. Data shows change from $422.10 Million to $132.23 Million (-9.20% CAGR). Check SCNX live share price for real-time trading data and today's change.
Index Memberships
Scienture Holdings, Inc. is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.00% | #719 of 976 |
Weight: Scienture Holdings, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Scienture Holdings, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Scienture Holdings, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Scienture Holdings, Inc. equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
48.52x
Scienture Holdings, Inc.'s market cap is 48.52 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $176.51 Million | $2.48 Million | -$2.76 Million | 71.12x | N/A |
| 2017 | $172.67 Million | $2.93 Million | $288.98K | 58.91x | 597.53x |
| 2018 | $115.12 Million | $3.83 Million | $9.04K | 30.04x | 12737.25x |
| 2019 | $422.10 Million | $7.44 Million | -$284.43K | 56.76x | N/A |
| 2020 | $2.03 Billion | $17.12 Million | -$2.54 Million | 118.55x | N/A |
| 2021 | $905.59 Million | $9.89 Million | -$5.32 Million | 91.57x | N/A |
| 2022 | $154.64 Million | $10.25 Million | -$3.47 Million | 15.09x | N/A |
| 2023 | $132.92 Million | $1.36 Million | -$17.84 Million | 97.46x | N/A |
| 2024 | $248.44 Million | $136.64K | $9.07 Million | 1818.15x | 27.40x |
| 2025 | $20.94 Million | $431.61K | -$41.51 Million | 48.52x | N/A |
Competitor Companies of SCNX by Market Capitalization
Companies near Scienture Holdings, Inc. in the global market cap rankings as of November 1, 2026. Also see Scienture Holdings, Inc. balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Scienture Holdings, Inc. by market ranking:
- JD HEALTH INTL LTD (F:8ZN): Ranked #1867 globally with a market cap of $12.04 Billion USD ( €10.30 Billion EUR).
- Walgreens Boots Alliance Inc (NASDAQ:WBA): Ranked #2108 globally with a market cap of $10.37 Billion USD.
- ALIB.HL.INF.TEC.UNSP.ADR (F:TWYA): Ranked #2442 globally with a market cap of $8.42 Billion USD ( €7.20 Billion EUR).
- Raia Drogasil S.A (SA:RADL3): Ranked #3350 globally with a market cap of $5.22 Billion USD ( R$26.61 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #1867 | JD HEALTH INTL LTD | F:8ZN | $12.04 Billion | €4.30 |
| #2108 | Walgreens Boots Alliance Inc | NASDAQ:WBA | $10.37 Billion | $11.98 |
| #2442 | ALIB.HL.INF.TEC.UNSP.ADR | F:TWYA | $8.42 Billion | €8.95 |
| #3350 | Raia Drogasil S.A | SA:RADL3 | $5.22 Billion | R$15.22 |
Market Capitalization of Scienture Holdings, Inc. (2015–2026)
Market capitalization of Scienture Holdings, Inc. from 2015 to today. Between 2015 and today, Scienture Holdings, Inc.'s market cap moved from $422.10 Million to $ 132.23 Million, with a yearly change of -9.20%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $132.23 Million | +531.37% |
| 2025 | $20.94 Million | -91.57% |
| 2024 | $248.44 Million | +86.91% |
| 2023 | $132.92 Million | -14.04% |
| 2022 | $154.64 Million | -82.92% |
| 2021 | $905.59 Million | -55.39% |
| 2020 | $2.03 Billion | +380.91% |
| 2019 | $422.10 Million | +266.66% |
| 2018 | $115.12 Million | -33.33% |
| 2017 | $172.67 Million | -2.18% |
| 2016 | $176.51 Million | -58.18% |
| 2015 | $422.10 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Scienture Holdings, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $15.07 Million USD |
| MoneyControl | $15.07 Million USD |
| MarketWatch | $15.07 Million USD |
| marketcap.company | $15.07 Million USD |
| Reuters | $15.07 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Scienture Holdings, Inc.
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of… Read more